Priority Date: 17.05.11 (EP 20110290232)

USE OF ANTI-CD19 MAYTANSINOID IMMUNOCONJUGATE ANTIBODY FOR THE TREATMENT OF B-CELL MALIGNANCIES SYMPTOMS

  • Application ID: EP12721529
  • Status: EXAMINATION IN PROGRESS

Applicant

Technology company logo small
Technology Company

Attorneys

no operation time available
2 offices
active in Legal Services
no operation time available
2 offices
Technology Company
no operation time available
2 offices
Technology Company

Specialization

This patent has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C07 (ORGANIC CHEMISTRY) is specialized in the combination A61 and C07. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Lederer Keller Patentanwälte Partnerschaft mbB, Vossius & Partner Patentanwälte Rechtsanwälte mbB, df-mp Dörries Frank-Molnia & Pohlman, Patentanwälte Rechtsanwälte PartG mbB and 186 others are specialized in all of these IPC classes. For a similar patent, they might be a good choice.

Timeline

  • 17.05.2011 - Priority Date (EP 20110290232)
  • 22.11.2012 - Publication A1 (WO2012156455)
  • 26.03.2014 - Publication A1 (EP2710034)

IPC Classification